Navigation Links
Analysis Confirms Diabetes Drug May Harm the Heart
Date:3/18/2011

THURSDAY, March 17 (HealthDay News) -- A new analysis confirms that those who take the diabetes drug Avandia are more likely to develop heart problems and die than those who take a similar type of diabetes medication.

"The effect on public health may be considerable," the analysis authors wrote.

Avandia (rosiglitazone) helps control blood sugar levels in the body, and is prescribed for patients with type 2 diabetes. Studies in recent years have differed about whether it boosts the risk of heart disease and death.

In response to growing concerns over the drug's cardiovascular effects, U.S. health officials in September restricted the use of Avandia to patients with type 2 diabetes who cannot control their disease on other medications.

In the new analysis, researchers looked at the results of 16 studies that involved 810,000 users of Avandia or Actos (pioglitazone), a similar diabetes medication. The findings appear online March 17 in the BMJ.

The researchers found a "modest but statistically significant increase" in the odds of certain heart conditions in those who took Avandia. The risk of heart attack rose by 16 percent and increased 23 percent for congestive heart failure. Overall, mortality rates rose 14 percent.

Avandia is a common drug, with about 3.8 million prescriptions a year in the United States.

The analysis authors cautioned that Actos carries its own risks. Like Avandia, it's been linked to a doubling of risk of fracture in women. And researchers worry that it may slightly boost the risk of bladder cancer.

"Patients should review this study with their physician to gain a better understanding of how their personal circumstances may or may not be reflected in the study, and talk to their physicians about the risks versus the benefit of taking the drug," said Dr. Debra Wertz, outcomes research manager for HealthCore Inc., the research subsidiary of the insurance company WellPoint.

Wertz co-authored a 2010 study that found no significant differences in risk of heart attack, heart failure or death in patients who took the two drugs.

"One thing to consider is that the HealthCore study evaluated a population that is commercially insured and potentially younger [most were under 65] and healthier" than the studies analyzed in the meta-analysis, Wertz noted.

More information

For more about diabetes, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Debra Wertz, Pharm.D., outcomes research manager, HealthCore Inc., Wilmington, Del.; March 17, 2011, BMJ


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Analysis Confirms Avandia May Harm the Heart
2. mygenomatix: A secure cloud-like model for next-gen sequencing data analysis
3. Tissue Analysis May Help Predict Breast Cancer Outcome
4. Peer Support Beats Usual Care for Depression, Analysis Finds
5. Competing risks analysis highlights new targets in preventing ESRD and death of diabetics
6. Zinc May Help Ease Common Cold: Analysis
7. Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say
8. Gay Teens Punished More Harshly Than Straight Peers: Analysis
9. Obesity Can Shorten Life, Analysis Finds
10. Pharmacists Improve Patient-Care Teams: Analysis
11. Mammals Grew Big After Dinosaurs Died Off: Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Analysis Confirms Diabetes Drug May Harm the Heart
(Date:9/25/2017)... ... 2017 , ... Physician Partners of America announces that Chad Gorman, M.D., has ... interventional pain management specialist. , Dr. Gorman is a board-certified physician specializing in ... In Brooksville, Fla. His orthopedic background puts him in a unique position to treat ...
(Date:9/25/2017)... ... September 25, 2017 , ... Leonard Bley, MD ... generation for LASIK in Manhattan with Contoura Vision, the latest WaveLight® topographic-guided laser ... available in the United States to correct nearsightedness and nearsightedness with astigmatism. This ...
(Date:9/25/2017)... ... September 25, 2017 , ... Dr. Edward Hebert ... “I could not imagine doing anything else,” said Dr. Hebert. “I count my blessings ... day. The interactions with my patients is what I look forward to the most. ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Ministry ... a gripping look at the religious stand in the sensitive matter of sexual ... compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing the ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... “The Majestic ... unicorns—during the great flood. “The Majestic Unicorn” is the creation of published author, Dayna ... or small, came from far and wide to march aboard the cypress ark-vessel. Male ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... Mass. , Sept. 1, 2017 ... HealthCare Solutions, Inc , highlights opportunities for growth in ... Journal report that Marlin Equity is seeking a buyer ... an annual award-winning 22-year-old healthcare solutions Value Added Reseller ... "As the healthcare ...
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: